vs
Apellis Pharmaceuticals, Inc.（APLS）与TEXAS CAPITAL BANCSHARES INC（TCBI）财务数据对比。点击上方公司名可切换其他公司
TEXAS CAPITAL BANCSHARES INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$324.0M vs $199.9M），TEXAS CAPITAL BANCSHARES INC净利率更高（22.8% vs -29.5%，领先52.3%），TEXAS CAPITAL BANCSHARES INC同比增速更快（15.5% vs -5.9%），过去两年TEXAS CAPITAL BANCSHARES INC的营收复合增速更高（10.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
德克萨斯资本银行总部位于美国得克萨斯州达拉斯，是得克萨斯资本 Bancshares 旗下的银行主体，在得州所有主要城市均设有线下网点，同时运营纯线上银行品牌Bask Bank，为客户提供多元便捷的金融服务。
APLS vs TCBI — 直观对比
营收规模更大
TCBI
是对方的1.6倍
$199.9M
营收增速更快
TCBI
高出21.4%
-5.9%
净利率更高
TCBI
高出52.3%
-29.5%
两年增速更快
TCBI
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $324.0M |
| 净利润 | $-59.0M | $73.8M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 22.8% |
| 营收同比 | -5.9% | 15.5% |
| 净利润同比 | -62.2% | 56.8% |
| 每股收益（稀释后） | $-0.40 | $1.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTCBI
| Q1 26 | — | $324.0M | ||
| Q4 25 | $199.9M | $327.5M | ||
| Q3 25 | $458.6M | $340.4M | ||
| Q2 25 | $178.5M | $307.5M | ||
| Q1 25 | $166.8M | $280.5M | ||
| Q4 24 | $212.5M | $229.6M | ||
| Q3 24 | $196.8M | $125.3M | ||
| Q2 24 | $199.7M | $267.0M |
净利润APLSTCBI
| Q1 26 | — | $73.8M | ||
| Q4 25 | $-59.0M | $100.7M | ||
| Q3 25 | $215.7M | $105.2M | ||
| Q2 25 | $-42.2M | $77.3M | ||
| Q1 25 | $-92.2M | $47.0M | ||
| Q4 24 | $-36.4M | $71.0M | ||
| Q3 24 | $-57.4M | $-61.3M | ||
| Q2 24 | $-37.7M | $41.7M |
营业利润率APLSTCBI
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 40.4% | ||
| Q3 25 | 48.7% | 40.5% | ||
| Q2 25 | -18.6% | 33.2% | ||
| Q1 25 | -50.0% | 21.6% | ||
| Q4 24 | -12.3% | 40.7% | ||
| Q3 24 | -24.0% | -63.8% | ||
| Q2 24 | -14.7% | 21.9% |
净利率APLSTCBI
| Q1 26 | — | 22.8% | ||
| Q4 25 | -29.5% | 30.7% | ||
| Q3 25 | 47.0% | 30.9% | ||
| Q2 25 | -23.6% | 25.2% | ||
| Q1 25 | -55.3% | 16.8% | ||
| Q4 24 | -17.1% | 30.9% | ||
| Q3 24 | -29.2% | -48.9% | ||
| Q2 24 | -18.9% | 15.6% |
每股收益（稀释后）APLSTCBI
| Q1 26 | — | $1.56 | ||
| Q4 25 | $-0.40 | $2.11 | ||
| Q3 25 | $1.67 | $2.18 | ||
| Q2 25 | $-0.33 | $1.58 | ||
| Q1 25 | $-0.74 | $0.92 | ||
| Q4 24 | $-0.30 | $1.43 | ||
| Q3 24 | $-0.46 | $-1.41 | ||
| Q2 24 | $-0.30 | $0.80 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $878.3M |
| 股东权益账面价值 | $370.1M | $3.6B |
| 总资产 | $1.1B | $33.5B |
| 负债/权益比越低杠杆越低 | — | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资APLSTCBI
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
总债务APLSTCBI
| Q1 26 | — | $878.3M | ||
| Q4 25 | — | $620.6M | ||
| Q3 25 | — | $620.4M | ||
| Q2 25 | — | $620.3M | ||
| Q1 25 | — | $660.5M | ||
| Q4 24 | — | $660.3M | ||
| Q3 24 | — | $660.2M | ||
| Q2 24 | — | $660.0M |
股东权益APLSTCBI
| Q1 26 | — | $3.6B | ||
| Q4 25 | $370.1M | $3.6B | ||
| Q3 25 | $401.2M | $3.6B | ||
| Q2 25 | $156.3M | $3.5B | ||
| Q1 25 | $164.2M | $3.4B | ||
| Q4 24 | $228.5M | $3.4B | ||
| Q3 24 | $237.1M | $3.4B | ||
| Q2 24 | $264.3M | $3.2B |
总资产APLSTCBI
| Q1 26 | — | $33.5B | ||
| Q4 25 | $1.1B | $31.5B | ||
| Q3 25 | $1.1B | $32.5B | ||
| Q2 25 | $821.4M | $31.9B | ||
| Q1 25 | $807.3M | $31.4B | ||
| Q4 24 | $885.1M | $30.7B | ||
| Q3 24 | $901.9M | $31.6B | ||
| Q2 24 | $904.5M | $29.9B |
负债/权益比APLSTCBI
| Q1 26 | — | 0.24× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSTCBI
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $360.2M | ||
| Q3 25 | $108.5M | $166.3M | ||
| Q2 25 | $4.4M | $63.0M | ||
| Q1 25 | $-53.4M | $368.0K | ||
| Q4 24 | $19.4M | $480.1M | ||
| Q3 24 | $34.1M | $332.8M | ||
| Q2 24 | $-8.3M | $33.3M |
自由现金流APLSTCBI
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $347.6M | ||
| Q3 25 | $108.3M | $161.3M | ||
| Q2 25 | $4.4M | $57.5M | ||
| Q1 25 | $-53.4M | $-2.0M | ||
| Q4 24 | $19.3M | $415.2M | ||
| Q3 24 | — | $317.6M | ||
| Q2 24 | $-8.4M | $11.1M |
自由现金流率APLSTCBI
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 106.1% | ||
| Q3 25 | 23.6% | 47.4% | ||
| Q2 25 | 2.5% | 18.7% | ||
| Q1 25 | -32.0% | -0.7% | ||
| Q4 24 | 9.1% | 180.9% | ||
| Q3 24 | — | 253.4% | ||
| Q2 24 | -4.2% | 4.1% |
资本支出强度APLSTCBI
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.8% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 28.2% | ||
| Q3 24 | 0.0% | 12.1% | ||
| Q2 24 | 0.0% | 8.3% |
现金转化率APLSTCBI
| Q1 26 | — | — | ||
| Q4 25 | — | 3.58× | ||
| Q3 25 | 0.50× | 1.58× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 6.76× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TCBI
暂无分部数据
